|
DUN (%) |
WGN (%) |
PLM (%) |
ARO (%) |
Combined (%) |
Total enrolled |
29 |
25 |
15 |
11 |
80 (100) |
Total completed |
28 (37.8) |
23 (31.1) |
13 (17.6) |
10 (13.5) |
74 (100) |
Average age (y) |
55.2 (32-84) |
52.1 (33-73) |
53.1 (29-74) |
55.3 (40-74) |
53.9 (32-84) |
Average weight (kg) |
71.4 ± 16.7 |
72.4 ± 16.1 |
77.5 ± 17.4 |
76.6 ± 14.8 |
73.5 ± 16.3 |
Ethnicity# |
|
NZ European |
25 (89.3) |
18 (78.3) |
11 (84.6) |
8 (80.0) |
62 (83.8) |
|
NZ Maori |
1 (3.6) |
3 (13.0) |
1 (7.7) |
0 (0) |
5 (6.8) |
|
Pacific Islander |
1 (3.6) |
0 (0) |
0 (0) |
0 (0) |
1 (1.4) |
|
European other |
1 (3.6) |
1 (4.3) |
0 (0) |
2 (20.0) |
4 (5.4) |
|
Fiji-Indian |
0 (0) |
1 (4.3) |
0 (0) |
0 (0) |
1 (1.4) |
|
Asian |
0 (0) |
1 (4.3) |
1 (7.7) |
0 (0) |
2 (2.7) |
Disease Stage |
|
I |
3 (10.7) |
1 (4.3) |
1 (7.7) |
0 (0) |
5 (6.8) |
|
II |
14 (50.0) |
4 (17.4) |
6 (46.2) |
5 (50.0) |
29 (39.2) |
|
III |
11 (39.3) |
17 (73.9) |
6 (46.2) |
5 (50.0) |
39 (52.7) |
|
N/A |
0 (0) |
1* * (4.3) |
0 (0) |
0 (0) |
1 (1.4) |
Treatment Modality |
|
Photons |
28 (100) |
23 (100) |
13 (100) |
3 (30.0) |
67 (90.5) |
|
Electrons |
0 (0) |
0 (0) |
0 (0) |
7 (70.0) |
7 (9.5) |
Prescribed Dose |
|
50Gy/25# |
26 (92.8) |
22 (95.7) |
10 (76.9) |
10 (100.0) |
68 (91.9) |
|
46Gy/20# |
1 (3.6) |
0 (0) |
0 (0) |
0 (0) |
1 (1.4) |
|
45Gy/25# |
0 (0) |
1 (4.3) |
0 (0) |
0 (0) |
1 (1.4) |
|
52Gy/26# |
1 (3.6) |
0 (0) |
0 (0) |
0 (0) |
1 (1.4) |
|
40Gy/15# |
0 (0) |
0 (0) |
3 (23.1) |
0 (0) |
3 (4.0) |
Bolus |
|
None |
22 (78.6) |
0 (0) |
1 (7.7) |
1 (10) |
24 (32.4) |
|
3 mm |
0 (0) |
23 (100) |
9 (69.2) |
1 (10.0) |
33 (44.6) |
|
4 mm |
0 (0) |
0 (0) |
0 (0) |
1 (10.0) |
1 (1.4) |
|
5 mm |
6 (21.4) |
0 (0) |
3 (23.1) |
7 (70.0) |
16 (21.6) |
Boost |
|
Yes |
0 (0) |
1 (4.3) |
0 (0) |
0 (0) |
1 (1.4) |
|
No |
28 (100) |
22 (95.7) |
13 (100) |
10 (100.0) |
73 (98.6) |
Axillary Node Dissection |
|
Yes |
24 (85.7) |
21 (91.3) |
13 (100) |
9 (90.0) |
67 (90.5) |
|
No |
4 (14.2) |
2 (8.7) |
0 (0) |
1 (10.0) |
7 (9.5) |
Chemotherapy |
|
None |
6 (21.4) |
3 (13.0) |
2 (15.4) |
2 (20.0) |
13 (17.6) |
|
Before RT |
22 (78.6) |
19 (82.6) |
3 (23.1 |
8 (80.0) |
52 (70.3) |
|
Concurrent |
0 (0) |
1 (4.3) |
8 (621.5 |
0 (0) |
9 (12.2) |
Fitzpatrick Skin type [17] |
|
I |
4 (14.2) |
2 (8.7) |
2 (15.4) |
0 (0) |
8 (10.8) |
|
II |
7 (25.0) |
6 (26.1) |
4 (30.8) |
0 (0) |
17 (23.0) |
|
III |
11 (39.3) |
10 (43.5) |
5 (38.5) |
9 (90.0) |
34 (45.9) |
|
IV |
5 (17.9) |
3 (13.0) |
1 (7.7) |
1 (10.0) |
10 (13.5) |
|
V |
1 (3.6) |
2 (8.7) |
1 (7.7) |
0 (0) |
4 (5.4) |
|
VI |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
Smoker |
|
Current |
2 (7.1) |
1 (4.3) |
1 (7.7) |
1 (10.0) |
5 (6.8) |
|
Ex |
7 (25.0) |
7 (30.4) |
3 (23.1) |
2 (20.0) |
19 (25.7) |
|
No |
19 (67.9) |
15 (65.2) |
9 (69.2) |
7 (70.0) |
50 (67.6) |
NS: not specified; NA: not applicable; * some people identify with more than one ethnicity;
**patient had a phyllodes tumour. |